Ultragenyx-Mereo's brittle bone drug sustains fracture rate cut in midphase follow-up

Ultragenyx and Mereo BioPharma have broken off another piece of brittle bone data, linking their drug candidate to sustained reductions in fracture rates in a midphase clinical trial.